GO:0046318 negative regulation of glucosylceramide biosynthetic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046318 describes any process that stops, prevents, or reduces the rate of glucosylceramide biosynthesis, a key step in glycosphingolipid metabolism.
• Glucosylceramide synthase (UGCG) is the central enzyme whose activity is negatively regulated; its inhibition blocks production of glucosylceramide and downstream glycosphingolipids.
• Negative regulation of glucosylceramide biosynthesis impacts viral replication, cell death, and lysosomal function, making it a target for antiviral and cancer research.
• Key regulators include ORMDL proteins, which modulate sphingolipid metabolism, and GBA1, whose deficiency alters glucosylceramide levels.
• Experimental models for studying this process include CRISPR knockout of UGCG or ORMDL genes, point mutations in GBA1, and overexpression of glucosylceramide synthase.
• Understanding this regulatory process offers insights into Gaucher disease, Parkinson's disease, and viral infections such as SARS-CoV-2 and influenza.
Description
Glucosylceramide (GlcCer) is the simplest glycosphingolipid and a precursor for more complex gangliosides and other glycosphingolipids. The biosynthetic process that produces GlcCer is tightly controlled, and its negative regulation—captured by the Gene Ontology term GO:0046318—is essential for maintaining cellular lipid homeostasis. This term encompasses any mechanism that reduces the frequency, rate, or extent of GlcCer formation, including inhibition of the enzyme glucosylceramide synthase (UGCG) or modulation of its substrates and regulators. Researchers study GO:0046318 because dysregulated GlcCer biosynthesis contributes to viral infection, lysosomal storage disorders, and cancer progression. For example, pharmacological inhibition of glucosylceramide synthase prevents replication of SARS-CoV-2 and influenza virus, highlighting the therapeutic potential of targeting this negative regulatory process. In addition, genetic models such as Drosophila mutants have shown that glucosylceramide synthase acts as a negative regulator of cell death mediated by proapoptotic factors. This article provides a research-grade overview of GO:0046318, covering its definition, biological significance, key genes, experimental models, and CRISPR-based methods for dissecting the negative regulation of glucosylceramide biosynthesis.
negative regulation of glucosylceramide biosynthetic process At A Glance
| GO ID | GO:0046318 |
|---|---|
| GO term | negative regulation of glucosylceramide biosynthetic process |
| Ontology | biological_process |
| Synonym | down regulation of glucosylceramide biosynthetic process; inhibition of glucosylceramide biosynthetic process; negative regulation of glucosylceramide formation |
| Major function | Reduces the rate of glucosylceramide synthesis, thereby controlling glycosphingolipid levels and downstream signaling. |
| Related enzyme | Glucosylceramide synthase (UGCG) |
| Related regulators | ORMDL proteins, GBA1 |
| Disease relevance | Viral infections, Gaucher disease, Parkinson's disease, cancer |
What Is GO:0046318?
GO:0046318 (negative regulation of glucosylceramide biosynthetic process) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide. In other words, it includes all molecular events that downregulate the production of glucosylceramide, a key glycosphingolipid intermediate.
Why Is negative regulation of glucosylceramide biosynthetic process Important in Cell Biology?
Negative regulation of glucosylceramide biosynthesis is critical for cellular lipid homeostasis and has broad implications for human health. Glucosylceramide serves as a precursor for hundreds of glycosphingolipids, and its overproduction is linked to viral replication, lysosomal dysfunction, and cancer progression. Conversely, too little glucosylceramide can impair membrane integrity and signaling. Understanding how this process is negatively regulated provides a foundation for developing therapies that target glucosylceramide synthase or its regulators.
• Controls the levels of glucosylceramide, a precursor for gangliosides and other glycosphingolipids.
• Inhibition of glucosylceramide synthase blocks replication of SARS-CoV-2 and influenza virus.
• Glucosylceramide synthase acts as a negative regulator of cell death mediated by proapoptotic factors.
• Deficiency in GBA1, which hydrolyzes glucosylceramide, leads to its accumulation and is linked to Parkinson's disease.
• ORMDL proteins regulate sphingolipid metabolism, including glucosylceramide biosynthesis.
• Modulating this process may offer therapeutic strategies for Gaucher disease and other lysosomal storage disorders.
• Altered glycosphingolipid levels affect cell migration and signaling, relevant to cancer metastasis.
• CRISPR-based knockout of UGCG or ORMDL genes enables precise dissection of this regulatory pathway.
What Happens During negative regulation of glucosylceramide biosynthetic process?
Inhibition of Glucosylceramide Synthase Activity
In simple terms: The enzyme that makes glucosylceramide is turned down or blocked.
The central step in glucosylceramide biosynthesis is the transfer of glucose to ceramide by glucosylceramide synthase (UGCG). Negative regulation of this process often involves direct inhibition of UGCG activity or reduction of its expression. Pharmacological inhibitors such as those tested against SARS-CoV-2 and influenza virus effectively block UGCG, thereby reducing glucosylceramide levels and impairing viral replication. In Drosophila, genetic studies have shown that glucosylceramide synthase can act as a negative regulator of cell death, indicating that its downregulation may have context-dependent effects on apoptosis.
Regulation by ORMDL Proteins
In simple terms: ORMDL proteins act like brakes on sphingolipid production, including glucosylceramide.
ORMDL proteins are evolutionarily conserved negative regulators of sphingolipid biosynthesis. CRISPR/Cas9 deletion of ORMDL proteins in human cells revealed complexity in sphingolipid metabolism, including effects on glucosylceramide levels. These proteins are thought to modulate serine palmitoyltransferase, the first enzyme in sphingolipid synthesis, thereby indirectly influencing the availability of ceramide for glucosylceramide production. Thus, ORMDL proteins contribute to the negative regulation of glucosylceramide biosynthetic process.
Impact of GBA1 on Glucosylceramide Turnover
In simple terms: GBA1 breaks down glucosylceramide; when it is deficient, glucosylceramide builds up.
Although GBA1 (lysosomal β-glucocerebrosidase) primarily hydrolyzes glucosylceramide rather than synthesizing it, its activity is critical for maintaining steady-state levels. GBA1 deficiency leads to accumulation of glucosylceramide and affects α-synuclein tetramers, linking this degradative pathway to Parkinson's disease. Therefore, negative regulation of glucosylceramide biosynthesis must be considered in the context of both synthetic and degradative arms of metabolism. Lipids can also regulate the hydrolysis of membrane-bound glucosylceramide by lysosomal β-glucocerebrosidase, adding another layer of control.
Downstream Effects on Glycosphingolipid Signaling
In simple terms: Reducing glucosylceramide changes the production of more complex lipids that affect cell behavior.
Glucosylceramide is the precursor for lactosylceramide, gangliosides, and other glycosphingolipids. Negative regulation of its biosynthesis therefore reduces the levels of these downstream molecules. For instance, lactosylceramide enhances Edwardsiella tarda infection, so inhibiting glucosylceramide production could limit bacterial infection. Similarly, GD3 ganglioside-enriched extracellular vesicles stimulate melanocyte migration, and reduced glucosylceramide would diminish GD3 synthesis. Src kinase mediates regulation of phospholipase C-gamma by glycosphingolipids, indicating that changes in glucosylceramide levels can alter intracellular signaling.
Key Genes Involved in GO:0046318 negative regulation of glucosylceramide biosynthetic process
The following genes and proteins are directly or indirectly involved in the negative regulation of glucosylceramide biosynthetic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGCG | Encodes glucosylceramide synthase, the enzyme that synthesizes glucosylceramide | Target for inhibitors; knockout reduces glucosylceramide and downstream glycosphingolipids |
| ORMDL1 | Negative regulator of sphingolipid biosynthesis | CRISPR deletion alters sphingolipid profiles including glucosylceramide |
| ORMDL2 | Negative regulator of sphingolipid biosynthesis | Modulates serine palmitoyltransferase and ceramide availability |
| ORMDL3 | Negative regulator of sphingolipid biosynthesis | Linked to asthma and sphingolipid metabolism; affects glucosylceramide |
| GBA1 | Lysosomal β-glucocerebrosidase that hydrolyzes glucosylceramide | Deficiency causes glucosylceramide accumulation and Parkinson's disease risk |
| B4GALT5 | Lactosylceramide synthase, converts glucosylceramide to lactosylceramide | Downstream of glucosylceramide; affects infection and signaling |
| B4GALT6 | Lactosylceramide synthase | Contributes to glycosphingolipid diversity |
| ST3GAL5 | GM3 synthase, uses lactosylceramide | Ganglioside synthesis downstream of glucosylceramide |
| ST8SIA1 | GD3 synthase, produces GD3 ganglioside | GD3-enriched EVs affect melanocyte migration |
| SRC | Kinase that mediates glycosphingolipid regulation of PLC-gamma | Links glucosylceramide-derived lipids to signaling |
| PLCG1 | Phospholipase C-gamma, regulated by glycosphingolipids | Downstream effector of glucosylceramide changes |
| SNCA | α-Synuclein, affected by GBA1 deficiency and glucosylceramide levels | Relevant to Parkinson's disease pathogenesis |
| SPTLC1 | Serine palmitoyltransferase subunit, first step in sphingolipid synthesis | Indirectly affects ceramide supply for glucosylceramide |
| SPTLC2 | Serine palmitoyltransferase subunit | Modulated by ORMDL proteins |
| KDSR | 3-ketodihydrosphingosine reductase, involved in sphingolipid synthesis | Affects ceramide availability |
| CERS2 | Ceramide synthase, produces very long-chain ceramides | Provides substrate for glucosylceramide synthesis |
| ASAH1 | Acid ceramidase, hydrolyzes ceramide | Balances ceramide and sphingosine pools |
How Is negative regulation of glucosylceramide biosynthetic process Regulated?
The negative regulation of glucosylceramide biosynthetic process is controlled at multiple levels. ORMDL proteins act as negative regulators of serine palmitoyltransferase, the rate-limiting enzyme in sphingolipid synthesis, thereby reducing ceramide availability for glucosylceramide production. Additionally, lipid environment and membrane composition can regulate the hydrolysis of glucosylceramide by lysosomal β-glucocerebrosidase, indirectly affecting steady-state levels. Pharmacological inhibitors of glucosylceramide synthase provide direct negative regulation and have been shown to block viral replication. In Drosophila, glucosylceramide synthase itself can act as a negative regulator of cell death, suggesting feedback mechanisms that link sphingolipid levels to apoptosis.
negative regulation of glucosylceramide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGCG | Viral replication (SARS-CoV-2, influenza) | CRISPR knockout in A549 or Vero cells, followed by viral infection |
| GBA1 | Gaucher disease, Parkinson's disease | Point mutation (e.g., L444P) knock-in in iPSCs or neuronal cells |
| ORMDL3 | Asthma, sphingolipid imbalance | CRISPR knockout in HEK293T or bronchial epithelial cells |
| B4GALT5 | Bacterial infection (Edwardsiella tarda) | Overexpression or knockout in intestinal epithelial cells |
| ST8SIA1 | Melanoma migration | Knockout in melanoma cell lines, assess EV-mediated migration |
Viral Infections
Glucosylceramide and its downstream glycosphingolipids are exploited by several viruses. Inhibition of glucosylceramide synthase, which negatively regulates glucosylceramide biosynthesis, prevents replication of SARS-CoV-2 and influenza virus in cell culture. This suggests that pharmacological or genetic downregulation of this pathway could serve as a broad-spectrum antiviral strategy. The mechanism may involve reduced availability of glycosphingolipid-rich membrane domains required for viral entry or assembly.
Parkinson's Disease and Gaucher Disease
Mutations in GBA1, the gene encoding lysosomal β-glucocerebrosidase, cause Gaucher disease and are a major risk factor for Parkinson's disease. GBA1 deficiency leads to accumulation of glucosylceramide, which negatively affects physiological α-synuclein tetramers and related multimers. Thus, impaired negative regulation of glucosylceramide biosynthesis—or failure to degrade it—contributes to neurodegeneration. Modulating glucosylceramide synthase activity may help restore lipid balance and mitigate α-synuclein pathology.
Cancer and Cell Migration
Glycosphingolipids derived from glucosylceramide influence cell migration and signaling. GD3 ganglioside-enriched extracellular vesicles stimulate melanocyte migration, and lactosylceramide enhances Edwardsiella tarda infection. Src kinase mediates the regulation of phospholipase C-gamma by glycosphingolipids, linking glucosylceramide metabolism to intracellular signaling pathways that can promote tumor progression. Therefore, negative regulation of glucosylceramide biosynthesis may suppress oncogenic signaling and metastasis.
From negative regulation of glucosylceramide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of UGCG reduce glucosylceramide and block viral replication? | UGCG knockout cell line (e.g., A549) via CRISPR/Cas9 |
| How do point mutations in GBA1 affect glucosylceramide levels and α-synuclein? | GBA1 L444P knock-in iPSC-derived neurons |
| Can overexpression of ORMDL3 negatively regulate glucosylceramide synthesis? | ORMDL3 overexpression in HEK293T cells |
| What is the role of glucosylceramide synthase in cell death? | Drosophila UGCG mutants or RNAi knockdown |
| Does lactosylceramide derived from glucosylceramide enhance bacterial infection? | B4GALT5 knockout or overexpression in epithelial cells |
| How does GD3 ganglioside affect melanocyte migration? | ST8SIA1 knockout melanoma cells and EV isolation |
How to Study the negative regulation of glucosylceramide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Quantitative levels of glucosylceramide and other sphingolipids | Assessing effects of UGCG inhibitors or ORMDL knockout |
| CRISPR knockout screening | Identification of genes affecting glucosylceramide levels | Discovery of novel negative regulators |
| Glucosylceramide synthase activity assay | Enzymatic conversion of ceramide to glucosylceramide | Testing inhibitors or activators |
| qPCR / RNA-seq | Expression of UGCG, ORMDL, GBA1 and related genes | Evaluating transcriptional regulation |
| Immunofluorescence | Subcellular localization of UGCG or ORMDL proteins | Linking lipid changes to organelle function |
| Viral replication assay | Viral titer after modulation of glucosylceramide synthesis | Antiviral drug screening |
| α-Synuclein multimer analysis | Tetramer/multimer levels in GBA1-deficient cells | Parkinson's disease modeling |
| Cell migration assay | Migration of melanocytes or cancer cells | Assessing GD3 ganglioside effects |
Lipidomics and Mass Spectrometry
Quantitative lipidomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring glucosylceramide and related sphingolipids. This method allows researchers to assess the impact of negative regulators such as ORMDL proteins or UGCG inhibitors on the entire sphingolipidome. Targeted analysis of glucosylceramide species can reveal subtle changes in biosynthesis rates.
CRISPR/Cas9 Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss alters glucosylceramide levels or viral replication. For example, CRISPR deletion of ORMDL proteins revealed complexity in sphingolipid metabolism. Such screens are powerful for discovering novel negative regulators of glucosylceramide biosynthesis.
Enzymatic Activity Assays
Glucosylceramide synthase activity can be measured in cell lysates using fluorescent or radioactive ceramide substrates. This allows direct assessment of whether a candidate regulator inhibits enzyme activity. Inhibitors of UGCG have been validated using such assays in antiviral studies.
Imaging and Subcellular Localization
Fluorescently tagged glucosylceramide or its analogs can be used to visualize its distribution and trafficking. Immunofluorescence of UGCG or ORMDL proteins can reveal changes in localization upon negative regulation. These methods help link lipid changes to cellular phenotypes such as viral entry or autophagy.
How CRISPR Can Be Used to Study GO:0046318 negative regulation of glucosylceramide biosynthetic process
Knockout
CRISPR/Cas9 knockout of UGCG or ORMDL genes is a direct way to study negative regulation of glucosylceramide biosynthesis. For example, UGCG knockout cells exhibit drastically reduced glucosylceramide levels and impaired viral replication. ORMDL knockout cells show altered sphingolipid profiles, revealing compensatory mechanisms. These models are essential for establishing causality.
Point Mutation
Introducing disease-relevant point mutations, such as GBA1 L444P, via CRISPR prime editing or homology-directed repair allows researchers to study how specific mutations affect glucosylceramide turnover and α-synuclein aggregation. Such models are more physiologically relevant than complete knockouts for understanding partial loss-of-function.
Knock-in
Knock-in of tagged UGCG or ORMDL proteins (e.g., GFP or HA tags) enables live-cell imaging and proteomic analysis of these regulators. Tagged knock-in models can reveal dynamic changes in protein localization and interactions upon negative regulation of glucosylceramide synthesis.
Overexpression
Overexpression of glucosylceramide synthase or ORMDL proteins can be achieved by CRISPR activation (CRISPRa) or lentiviral delivery. Overexpression of ORMDL3 negatively regulates sphingolipid biosynthesis, including glucosylceramide, and can be used to study downstream effects on cell signaling and viral infection.
How EDITGENE Supports negative regulation of glucosylceramide biosynthetic process Research
Researchers studying negative regulation of glucosylceramide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in controlling glucosylceramide levels, and to dissect the downstream consequences for viral infection, neurodegeneration, or cancer. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glucosylceramide biosynthetic process research.
Frequently Asked Questions About negative regulation of glucosylceramide biosynthetic process
What is GO:0046318?
GO:0046318 is the Gene Ontology term for negative regulation of glucosylceramide biosynthetic process, defined as any process that stops, prevents, or reduces the rate of glucosylceramide formation.
What genes are involved in negative regulation of glucosylceramide biosynthetic process?
Key genes include UGCG (glucosylceramide synthase), ORMDL1/2/3, GBA1, and downstream enzymes such as B4GALT5 and ST8SIA1.
How is glucosylceramide biosynthesis negatively regulated?
It can be negatively regulated by inhibition of UGCG enzyme activity, by ORMDL proteins that reduce ceramide availability, or by pharmacological inhibitors.
Why is negative regulation of glucosylceramide biosynthesis important for viral infections?
Inhibiting glucosylceramide synthase blocks replication of SARS-CoV-2 and influenza virus, suggesting this pathway is a potential antiviral target.
What diseases are linked to glucosylceramide metabolism?
Gaucher disease, Parkinson's disease, and certain cancers are linked to altered glucosylceramide levels.
How can CRISPR be used to study this process?
CRISPR knockout of UGCG or ORMDL genes, point mutation knock-in of GBA1, and overexpression of regulators allow precise dissection of the pathway.
What is the role of ORMDL proteins in glucosylceramide regulation?
ORMDL proteins negatively regulate serine palmitoyltransferase, reducing ceramide supply for glucosylceramide synthesis.
Does GBA1 deficiency affect glucosylceramide levels?
Yes, GBA1 deficiency leads to glucosylceramide accumulation and is associated with Parkinson's disease risk.
What experimental models are used to study negative regulation of glucosylceramide biosynthesis?
Common models include UGCG knockout cell lines, GBA1 mutant iPSCs, ORMDL knockout HEK293T cells, and Drosophila mutants.
How does glucosylceramide affect cell death?
In Drosophila, glucosylceramide synthase acts as a negative regulator of cell death mediated by proapoptotic factors.
Conclusion
GO:0046318, negative regulation of glucosylceramide biosynthetic process, is a critical control point in sphingolipid metabolism with far-reaching implications for viral infection, neurodegeneration, and cancer. The interplay between glucosylceramide synthase, ORMDL proteins, and GBA1 determines cellular glucosylceramide levels and downstream glycosphingolipid signaling. By leveraging CRISPR-based knockout, point mutation, knock-in, and overexpression models, researchers can precisely dissect this regulatory pathway. EDITGENE offers end-to-end services to accelerate discovery in this field, from custom cell line generation to high-throughput screening and bioinformatics.
References
- 1. Oishi K et al.. 2021. Host lactosylceramide enhances Edwardsiella tarda infection.. Cell Microbiol 23(9):e13365 PMID: 33988901
- 2. Kohyama-Koganeya A et al.. 2004. Drosophila glucosylceramide synthase: a negative regulator of cell death mediated by proapoptotic factors.. J Biol Chem 279(34):35995-6002 PMID: 15210713
- 3. Abdul-Hammed M et al.. 2017. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase.. J Lipid Res 58(3):563-577 PMID: 28126847
- 4. Vitner EB et al.. 2021. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.. J Biol Chem 296:100470 PMID: 33639165
- 5. Otake AH et al.. 2019. G(D3) ganglioside-enriched extracellular vesicles stimulate melanocyte migration.. Biochim Biophys Acta Mol Cell Biol Lipids 1864(3):422-432 PMID: 29908366
- 6. Shu L et al.. 2003. Src kinase mediates the regulation of phospholipase C-gamma activity by glycosphingolipids.. J Biol Chem 278(33):31419-25 PMID: 12771140
- 7. Kim S et al.. 2018. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers.. Proc Natl Acad Sci U S A 115(4):798-803 PMID: 29311330
- 8. Green CD et al.. 2021. CRISPR/Cas9 deletion of ORMDLs reveals complexity in sphingolipid metabolism.. J Lipid Res 62:100082 PMID: 33939982
